Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.

OBJECTIVE: Budesonide MMX is a novel oral formulation of budesonide that uses Multi-Matrix System (MMX) technology to extend release to the colon. This study compared the efficacy of budesonide MMX with placebo in patients with active, mild-to-moderate ulcerative colitis (UC). DESIGN: Patients were...

Full description

Bibliographic Details
Main Authors:	Travis, S, Danese, S, Kupcinskas, L, Alexeeva, O, D'Haens, G, Gibson, P, Moro, L, Jones, R, Ballard, E, Masure, J, Rossini, M, Sandborn, W
Format:	Journal article
Language:	English
Published:	2014

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.

Similar Items